UK Markets closed

ABIONYX Pharma SA (0RAG.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
1.8444-0.2041 (-9.97%)
At close: 05:41PM GMT

ABIONYX Pharma SA

33 43 av. Georges Pompidou Bât. D2
Balma 31130
France
33 5 62 24 97 06
https://abionyx.com

Sector(s)
Industry
Full-time employees62

Key executives

NameTitlePayExercisedYear born
Sir Cyrille Tupin CPACEO, GM & Director4.64MN/A1977
Prof. Christian Chavy MBAIndependent Director28kN/A1950
Mr. Emmanuel De FougerouxChief Accounting Officer & CFON/AN/AN/A
Ms. Renee BenghoziChief Medical OfficerN/AN/AN/A
Mr. Gavin SyChief Production OfficerN/AN/AN/A
Ms. Constance KeyserlingSr. VP of Clinical Devel.N/AN/A1961
Amounts are as of 31 December 2018, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. It has a strategic partnership with GTP Biologics and VBI Therapeutics Group for the bioproduction of the bio-HDL in France. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Balma, France.

Corporate governance

ABIONYX Pharma SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.